(UroToday.com) Following presentations from Dr. Fizazi discussing the role of abiraterone in combination with docetaxel for men with metastatic castration sensitive prostate cancer (mCSPC) and Dr. Attard discussing its role in combination with ADT for men being treated for high-risk, non-metastatic prostate cancer, Dr. Eleni Efstathiou provided an invited discussion to contextualize these results in the Proffered Paper session of the European Society for Medical Oncology (ESMO) Annual Congress focusing on prostate cancer genitourinary tumors.